Aligos Completes Enrollment in Phase 2 HBV Trial, Data Expected Late 2027
ALGS sits 44% above its 52-week low of $4.8 on light trading volume (0.4× avg).
Summary
Aligos has fully enrolled its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic HBV, with 131 HBeAg+ and 114 HBeAg- participants. This marks a key clinical milestone for the company's lead asset, which already has FDA Fast Track designation and a licensing deal with Amoytop Biotech that brought in a $25 million upfront payment. The enrollment completion de-risks the trial timeline and keeps the program on track for topline data in late Q3 2027. With a market cap around $41 million and a cash runway only into Q4 2026, positive Phase 2 data could be transformative for the company's valuation and partnership prospects.
At the time of this announcement, ALGS was trading at $6.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41M. The 52-week trading range was $4.80 to $13.69. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.